199 References: 41 Figures: 3 Table: 2 Abstract Background: Diagnostic uncertainty in ALS has serious management implications and delays recruitment into clinical trials. Emerging evidence of presymptomatic disease-burden provides the rationale to develop diagnostic applications based on the evaluation of in-vivo pathological patterns early in the disease.
Introduction
Patients with ALS often describe tripping, intermittent slurred speech, muscle cramping, leg stiffness years before their formal diagnosis. Delays in diagnosis compromises timely enrolment in clinical trials, and limit the neuroprotective potential of new therapeutic agents. It is now also widely recognized that a long presymptomatic phase precedes symptom manifestation. [1] The few existing presymptomatic studies ALS confirm that the pathological changes can be captured well before symptom onset. [2] The diagnosis of ALS remains primarily clinical, despite the unprecedented advances in quantitative neuroimaging and the uniquely specific imaging signature of ALS. After years of descriptive MRI studies in ALS, a number of studies have now emerged outlining diagnostic and prognostic applications based on pattern recognition. [3] While methods of machine learning and data mining have been extensively used in marketing, information technology, banking, traffic control and metrology, they have only been recently applied to neurodegeneration. [4] We hypothesized that based on the distinct neuroimaging signature of ALS a robust diagnostic framework can be outlined using discriminant function analysis. Our objective was to describe a diagnostic classification approach which incorporates multiple, ALS-defining, cortical, basal ganglia and white matter measures. The overarching hypothesis of this study is that 'data biopsies' from blinded data sets can be used to accurately categorize individual participants as patients or controls based on normative and disease-specific training data.
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Methods
All participants of this prospective biomarker study provided informed consent in accordance with the Medical Ethics Approval of the project (Beaumont Hospital, Dublin, Ireland). ALS patients and controls were randomly allocated in a 'training group' and a 'testing group' for validation. In total, 55 ALS patients and 55 controls were allocated to the 'training group' and 20 patients and 20 controls to the 'testing group'. Healthy controls have been specifically recruited for this ALS biomarker study.
The demographic and clinical profile of study participants are presented in 
Methods overview
The schematic overview of the development of the diagnostic protocol is presented in Figure 1 . First, comparative analyses were carried out between the patients and controls of the training group to establish core ALS-associated patterns of degeneration. Whole-brain tract-based spatial statistics (TBSS), voxel based morphometry and basal ganglia volumetrics were carried out correcting for age and gender, the methods of which have been described previously described. [5] [6] [7] [8] Additionally, the volumes of brain stem, left and right thalamus, caudate, pallidum, hippocampus, amygdala,
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putamen and accumbens nuclei were compared between the controls and ALS patients of the training group correcting for age. The main 'disease-defining' anatomical structures identified by these comparisons included the corticospinal tracts (CST), corpus callosum (CC), primary motor cortex (PMC), thalamus, caudate nuclei, accumbens nuclei, amygdala and the hippocampus.
Accordingly, region-of-interest (ROIs) anatomical maps were created for these structures, including voxels which showed statistically significant differences between patients and controls in the corticospinal tracts, corpus callosum, and precentral gyrus.
Figure 1. A schematic outline of model development, testing and validation
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Imaging data of both the training and testing groups have been spatially co-registered to the MNI reference system and averaged MR metrics were retrieved from each participant in the above ROIs.
In summary, our standardized 'virtual brain biopsy' consisted of retrieving quantitative MRI metrics from key, ALS-associated brain regions in each participant which were then evaluated in a discriminant function model. The outcomes of the initial comparisons and the atlas-based ROI masks created based on these contrasts are presented in Figure 2 . 
MRI Processing pipelines
Raw diffusion tensor imaging datasets underwent eddy current corrections, motion correction and brain-tissue extraction using FMRIB's software library (FSL). [9] A diffusion tensor model was then fitted, generating maps of axial diffusivity (AD), radial diffusivity (RD) and fractional anisotropy (FA).
Tract-based spatial statistics (TBSS) and permutation-based nonparametric inference was used for group comparisons in a study-specific white matter template applying the threshold-free cluster enhancement (TFCE) method. 
Region of interest maps
The grey matter region of interest (ROI) for the left and right primary motor cortex was created based on the Harvard-Oxford probabilistic atlas [13] and defined based on voxels of the primary motor cortex which showed statistically significant differences at p<0.05 between controls and 
Predictor variables after candidate predictor assessment and selection
Average RD in the "right RD corticospinal tract ROI" Average RD in the "left RD corticospinal tract ROI" Average RD in the "RD corpus callosum ROI" Average AD in the "right AD corticospinal tract ROI" Average AD in the "left AD corticospinal tract ROI" Average AD in the "AD corpus callosum ROI" T1-signal intensity in the "right motor cortex ROI" T1-signal intensity in the "left motor cortex ROI" Averaged volume of the left and right thalamus Averaged volume of the left and right caudate Volume of the left hippocampus Volume of the right hippocampus Volume of the left nucleus accumbens Volume of the right nucleus accumbens Volume of the left amygdala 
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Results
The canonical discriminant function reached an Eigen value of 0.871, a canonical correlation value of 0.682, Wilks lambda of 0.534, Chi-square 62.983 and a significance of less than 0.001. The model showed an overall classification sensitivity of 89.1% and specificity of 85.5% in the 'training' group. In the 'testing sample' both sensitivity and specificity reached 90%. Classification function outcomes, histograms and scatter plots of discriminant score distributions are shown in Figure 3 . 
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Discussion
Neuroimaging in ALS has been very successful in characterizing group-level, disease-specific changes [18] [19] [20] [21] , and also in describing phenotype [5 22 23] and genotype-specific [24 25 ] neuroimaging signatures. More recently, ALS MRI studies captured presymptomatic imaging alterations. [2 26 27] Despite the significant advances in group-level, cross-sectional [28] and longitudinal analyses [29 30] in neurodegenerative conditions, the interpretation of single data sets remains methodologically challenging and a striking paucity of such studies persists in ALS. [31] [32] [33] [34] are likely to improve diagnostic classification further as they have been previously shown to be sensitive longitudinal and prognostic markers in ALS. [38] [39] [40] [41] 
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A range of statistical methods are available to classify blinded data in neurodegeneration, and each method is associated with unique advantages and limitations. Despite the relatively restrictive assumptions of discriminant function analyses, the advantage of this approach is that it readily integrates multiple measures, and provides diagnostic probabilities in addition to discriminant scores. Until robust, multi-center classification studies are published in ALS, it remains to be seen which approach is best suited to reliably capture early pathological changes in vivo. The concept of ROI-based, spatial reference system guided 'data biopsies' is also applicable to longitudinal analyses and potentially for the development of future monitoring markers.
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